Moderate

Chronic pulmonary aspergillosis

aspergilloma / CPA · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic pulmonary aspergillosis is a slowly progressive Aspergillus infection in patients with pre-existing lung cavities or damage (prior TB, NTM, sarcoid, COPD). It ranges from a simple aspergilloma to chronic cavitary and fibrosing disease and is distinct from ABPA and invasive aspergillosis.

Red flags

  • Massive haemoptysis
  • Rapid cavity enlargement or systemic deterioration (consider invasive disease)
  • Significant weight loss and cachexia
  • Azole hepatotoxicity or QT prolongation

Assessment

Differential diagnosis

  • Reactivation tuberculosis
  • Non-tuberculous mycobacterial disease
  • Lung cancer
  • ABPA
  • Invasive aspergillosis
  • Chronic bacterial infection

Investigations

  • CT chest (cavity with fungal ball/mycetoma, pleural thickening, progressive cavitation)
  • Aspergillus-specific IgG (precipitins) — key serological test
  • Sputum/BAL culture and Aspergillus PCR, galactomannan
  • Exclude active TB (AFB, culture)
  • Spirometry and nutritional assessment
  • Inflammatory markers to monitor activity

Management

  • Suspect in chronic respiratory symptoms with cavitary lung disease and weight loss
  • Confirm with Aspergillus IgG positivity plus compatible imaging over >=3 months
  • Exclude active TB and malignancy as alternative causes
  • Classify: simple aspergilloma vs chronic cavitary/fibrosing aspergillosis
  • Treat symptomatic or progressive disease with long-term oral azole therapy
  • Monitor azole levels, LFTs, QTc and drug interactions
  • Reserve intravenous/alternative antifungals for azole failure or resistance
  • Consider surgical resection for localised disease or life-threatening haemoptysis in fit patients
  • Use bronchial artery embolisation for significant haemoptysis
  • Monitor long term with imaging, IgG trends and symptom/weight assessment

Drugs & doses

Itraconazole 200 mg PO twice daily (with level monitoring)
Voriconazole 200 mg PO twice daily (alternative/first-line, monitor levels)
Posaconazole 300 mg PO once daily (after loading) for azole intolerance/resistance
Liposomal amphotericin B / micafungin IV for severe azole-refractory disease

Disposition

Specialist respiratory / national aspergillosis service; thoracic surgery and interventional radiology for haemoptysis; long-term monitoring.

Complications & pitfalls

  • Life-threatening haemoptysis
  • Progressive pulmonary fibrosis and respiratory failure
  • Azole toxicity and resistance
  • Secondary bacterial infection

Exam pearls

  • Aspergillus IgG (precipitins) is the single most useful diagnostic test for CPA
  • A simple aspergilloma in a single cavity may be managed with observation or surgery rather than lifelong azoles
  • Bronchial artery embolisation controls haemoptysis but is often a temporising measure
  • Azole resistance is rising — check levels and susceptibilities in non-responders

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.